Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Հիմնական հեղինակներ: | Aoki, Y, Wood, MJA |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
IOS Press
2021
|
Նմանատիպ նյութեր
-
Oligonucleotide-based therapies for neuromuscular disease
: Douglas, A, և այլն
Հրապարակվել է: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
: Tsoumpra, MK, և այլն
Հրապարակվել է: (2019) -
Advances in oligonucleotide drug delivery
: Roberts, TC, և այլն
Հրապարակվել է: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
: Ashok Verma
Հրապարակվել է: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
: Gait, M, և այլն
Հրապարակվել է: (2018)